Dr. Sundarakrishnan is a Biomedical Engineer by training, and he has a B.S. and M.S. from Drexel University (Philadelphia, PA), and a PhD from Tufts University (Medford, MA). He completed postdoctoral traineeships in Chemical & Biological Engineering at Princeton University (Princeton, NJ), and Developmental & Cell Biology at SickKids Hospital, which is affiliated with the University of Toronto. Dr. Sundarakrishnan currently holds the title of Assistant Professor at the University of Wisconsin Eau Claire’s Dept. of Materials Science and Biomedical Engineering. He is the principal investigator at S-LAB, which involves several talented students at the University of Wisconsin—Eau Claire (UWEC). Prior to joining UWEC, Dr. Sundarakrishnan taught graduate-level courses in Biotechnology & Bioengineering at Northeastern University—Toronto and at the Toronto Metropolitan University.
Learn more about Dr. Sundarakrishnan
Abstract: Engineering in-vitro models of human lung disease using di-tyrosine chemistry
With the COVID-19 pandemic, and worsening air-quality in urban areas, the lung is one of the most widely studied organs in the human body, and it is highly susceptible to injury. As biomedical engineers we are extremely interested in modeling the lung, but the lung has 40+ different cell types, and it is made up of hundreds of different extracellular matrix proteins. Most current models of the human lung focus on reductionist approaches in the laboratory, recapitulating an anatomical subset, or disease process, often including a smaller subset of cells and extracellular matrix (ECM) proteins. The focus of this talk will be on reductionist in-vitro lung models that utilize di-tyrosine chemical bonding, which is found in almost every major ECM protein in the human lung, including most collagen-subtypes and elastin. We will compare in-vitro model systems with rodent models, as these are still the most widely used pre-clinical models of assessment in the laboratory.
Free radicals from different sources (e.g., lung cells or external sources), along with peroxidase enzymes (e.g., myeloperoxidase) drive the formation of di-tyrosine crosslinks in the human lung ECM. In this talk we will look at recent studies, including studies from our laboratory, that have induced di-tyrosine crosslinking within either in-vitro or in-vivo systems to study lung pathology. We will look at methods used to induce di-tyrosine crosslinking, while also looking at how results from these studies connect to broader pathological mechanisms driving lung disease states such as fibrosis, cancer, and aging.